Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minalrestat SCHEMBL29727574 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| Minalrestat SCHEMBL30602643 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| Minalrestat SCHEMBL9384195 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| Minalrestat SCHEMBL9388567 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9383175 | 0.92 | AKR1B1 (0.85) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9384248 | 0.90 | AKR1B1 (0.82) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL8806173 | 0.89 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9383561 | 0.89 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9383384 | 0.89 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9383986 | 0.84 | AKR1B1 (0.77) | AKR1B1AKR1B10AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1694 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374693-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2024-11-14 | — | — | US | claimed |
| US-12083168-B2 | Treatment and detection of inherited neuropathies and associated disorders | UNIVERSITY OF MIAMI (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024053761-A1 | COMPOSITION FOR PROMOTING MYOBLAST PROLIFERATION AND DIFFERENTIATION CONTAINING ALDOSE REDUCTASE INHIBITOR | 애니머스큐어 주식회사 | 2024-03-14 | — | — | WO | claimed |
| US-20240003908-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-01-04 | — | — | US | claimed |
| US-20230293642-A9 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2023-09-21 | — | — | US | claimed |
| EP-4244243-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | Mayo Foundation for Medical Education and Research (US) | 2023-09-20 | — | — | EP | claimed |
| US-20220249624-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIV MIAMI (US) | 2022-08-11 | — | — | US | claimed |
| WO-2022103815-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAGGIES PEARL LLC (US) | 2022-04-28 | — | — | US | claimed |
| US-20220125890-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2022-04-28 | — | — | US | claimed |
| EP-1064964-A2 | Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1064965-A2 | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1064949-A2 | Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| WO-2000045818-A1 | USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | claimed |
| CN-1261804-A | Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor | ZENECA LTD (GB) | 2000-08-02 | — | — | CN | claimed |
| EP-0991424-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALDOSE REDUCTASE INHIBITOR AND AN ACE INHIBITOR | ZENECA LIMITED (GB) | 2000-04-12 | — | — | EP | claimed |
| WO-1999002189-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALDOSE REDUCTASE INHIBITOR AND AN ACE INHIBITOR | ZENECA LIMITED (GB) | 1999-01-21 | — | — | WO | claimed |
| EP-0365324-B1 | Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors | AMERICAN HOME PROD (US) | 1994-05-04 | — | — | EP | claimed |
| US-4927831-A | PREVENTION OF DIABETES MELLITUS ASSOCIATED COMPLICATIONS | AMERICAN HOME PRODUCTS (US) | 1990-05-22 | — | — | US | claimed |
| EP-0365324-A1 | Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAN1B1, MAN2B1, GAA | AKR1B1 1383/4885AKR1B10 1399/4885AKR1A1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.